Developmental Research Program

发展研究计划

• 批准号: 10005148
• 负责人: Timothy Charles Thompson
• 金额: $ 15.41万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-02 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10005148
• 关键词: Area; Award; Awareness; Basic Science; Cancer Center; Cancer Patient; Clinical; Clinical Research; Collaborations; Communities; Complement; Development; Educational Activities; Environment; Evaluation; Funding; Funding Mechanisms; Goals; Grant; Human; Incidence; Institution; Laboratories; Leadership; Letters; Malignant neoplasm of prostate; Minority; Modeling; Monitor; National Cancer Institute; Participant; Peer Review Grants; Pilot Projects; Population; Principal Investigator; Process; Program Research Project Grants; Progress Reports; Publications; Quality of life; Reproduction spores; Research; Research Personnel; Research Project Grants; Research Support; Scientist; Selection Criteria; Survival Rate; Translating; Translational Research; United States National Institutes of Health; Woman; anticancer research; base; career; flexibility; improved; innovation; member; mortality; organizational structure; programs; recruit; research study; screening program; success; translational scientist

PROJECT SUMMARY (Developmental Research Program) The goal of the Developmental Research Program (DRP) of the MD Anderson Cancer Center Prostate Cancer SPORE is to fund promising studies in translational prostate cancer research. It is directed by Dr. Timothy C. Thompson and co-directed by Dr. Christopher J. Logothetis. As with our current SPORE, the DRP in this renewal will emphasize the support of translational research studies that can generate clinically testable hypotheses to help reduce the incidence and mortality of prostate cancer and/or improve the quality of life of prostate cancer patients. The Prostate Cancer SPORE Administrative Core has established a broad-based effort for solicitation of potential DRP projects. Letters of intent of no more than 2 pages for innovative translational research are invited from MD Anderson and outside institutions and SPORE and non-SPORE investigators, including participants in the SPORE Career Enhancement Program. These applications will be screened by the program Director and co-Director (who also serve as the SPORE Principal investigator and co-Principal Investigator) according to objective criteria. Investigators of selected applications will be asked to prepare a 5-page proposal modeled after a National Institutes of Health R01. As appropriate, the Administrative Core Directors and staff will assist investigators submitting proposals formulate translational specific aims and research plans, as many of these investigators will not have expertise in these areas. The process constitutes a major educational activity and will further stimulate the development of innovative translational research concepts. The proposals will be reviewed and prioritized by the Prostate Cancer SPORE Leaders (Principal Investigators, Project co-Leaders, Program Directors, and Core Directors). The projects will be funded for 1 year and will be renewable for an additional year on the basis of established criteria. Developmental Research projects will be evaluated ad hoc and annually by the program Director/co- Director, SPORE Leaders, Executive Committee, and combined Internal/External Advisory Boards. The DRP has established a mechanism for termination of projects that do not meet our criteria for continuation; however, it has not been necessary to utilize this mechanism in the DRP to date. Nine developmental projects were funded in the current Prostate Cancer SPORE. Investigators receiving DRP grants wrote 29 publications related to the research supported by their grants during 2009-2014 and were awarded 19 external peer-reviewed grants. Importantly, 2 DRP awardees are investigators for major projects in the Prostate Cancer SPORE renewal application: Drs. Sue-Hwa Lin (co-Leader, Project 2) and Padmanee Sharma (co-Leader, Project 1), highlighting the importance of the DRP in identifying projects and investigators with potential value for translational research.

项目摘要（发展研究计划） MD 安德森癌症中心前列腺发展研究计划 (DRP) 的目标 Cancer SPORE 旨在资助转化前列腺癌研究中颇有前景的研究。它是由博士指导的。 蒂莫西·C·汤普森 (Timothy C. Thompson) 和克里斯托弗·J·洛格西提斯 (Christopher J. Logothetis) 博士联合执导。与我们当前的 SPORE 一样，DRP 在这次更新中将强调对转化研究的支持，这些研究可以产生可临床测试的结果 有助于降低前列腺癌的发病率和死亡率和/或提高生活质量的假设 前列腺癌患者。前列腺癌 SPORE 管理核心建立了一个基础广泛的 努力征集潜在的 DRP 项目。不超过2页的创新意向书 MD安德森和外部机构以及SPORE和非SPORE邀请转化研究 调查员，包括 SPORE 职业提升计划的参与者。这些应用程序将 由项目主任和联合主任（同时担任 SPORE 首席研究员和 联合首席研究员）根据客观标准。选定申请的研究人员将被要求 以国立卫生研究院 R01 为蓝本，准备一份 5 页的提案。根据情况， 行政核心董事和工作人员将协助调查人员提交提案、制定转化方案 具体目标和研究计划，因为许多研究人员不具备这些领域的专业知识。这 过程是一项重大的教育活动，将进一步激发创新发展 转化研究概念。这些提案将由前列腺癌委员会进行审查和优先排序 SPORE 领导者（首席研究员、项目联合领导者、项目总监和核心总监）。这 项目的资助期为一年，并可在既定的基础上再续展一年 标准。发展研究项目将由项目主任/共同评估每年一次 董事、SPORE 领导人、执行委员会以及内部/外部联合顾问委员会。发展计划 建立了终止不符合我们继续标准的项目的机制； 然而，迄今为止，DRP 中还没有必要使用这一机制。 目前的前列腺癌 SPORE 资助了九个开发项目。接受 DRP 的调查人员 2009 年至 2014 年期间，他们撰写了 29 篇与其资助支持的研究相关的出版物， 授予 19 项外部同行评审资助。重要的是，2 位 DRP 获奖者是重大项目的研究者 在前列腺癌 SPORE 更新申请中： Drs. Sue-Hwa Lin（项目 2 联合负责人）和 Padmanee Sharma（项目 1 联合负责人）强调 DRP 在确定项目和研究人员方面的重要性 具有转化研究的潜在价值。